- Home
- BNRG vs VRAX Comparison
BNRG vs VRAX Comparison
Compare BNRG & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- VRAX
- Stock Information
- Founded
- BNRG 2012
- VRAX 2013
- Country
- BNRG Israel
- VRAX United Kingdom
- Employees
- BNRG N/A
- VRAX N/A
- Industry
- BNRG
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BNRG
- VRAX Health Care
- Exchange
- BNRG Nasdaq
- VRAX Nasdaq
- Market Cap
- BNRG 5.2M
- VRAX 4.4M
- IPO Year
- BNRG 2022
- VRAX 2022
- Fundamental
- Price
- BNRG $2.17
- VRAX $0.64
- Analyst Decision
- BNRG
- VRAX Strong Buy
- Analyst Count
- BNRG 0
- VRAX 1
- Target Price
- BNRG N/A
- VRAX $3.00
- AVG Volume (30 Days)
- BNRG 57.8K
- VRAX 1.6M
- Earning Date
- BNRG 08-13-2025
- VRAX 01-01-0001
- Dividend Yield
- BNRG N/A
- VRAX N/A
- EPS Growth
- BNRG N/A
- VRAX N/A
- EPS
- BNRG N/A
- VRAX N/A
- Revenue
- BNRG N/A
- VRAX $6,331.00
- Revenue This Year
- BNRG N/A
- VRAX $217,274.83
- Revenue Next Year
- BNRG N/A
- VRAX N/A
- P/E Ratio
- BNRG N/A
- VRAX N/A
- Revenue Growth
- BNRG N/A
- VRAX N/A
- 52 Week Low
- BNRG $1.64
- VRAX $0.52
- 52 Week High
- BNRG $15.30
- VRAX $3.62
- Technical
- Relative Strength Index (RSI)
- BNRG 52.30
- VRAX 46.81
- Support Level
- BNRG $2.10
- VRAX $0.59
- Resistance Level
- BNRG $2.30
- VRAX $0.70
- Average True Range (ATR)
- BNRG 0.14
- VRAX 0.05
- MACD
- BNRG 0.00
- VRAX 0.01
- Stochastic Oscillator
- BNRG 47.56
- VRAX 69.78
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).